HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andrew Wardley Selected Research

Trastuzumab (Herceptin)

5/2021The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
1/2021Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
10/2020Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
12/2016Trastuzumab-associated cardiac events in the Persephone trial.
5/2013AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
3/2013CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
3/2010Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.
2/2010Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated.
11/2009Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
2/2009Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andrew Wardley Research Topics

Disease

35Breast Neoplasms (Breast Cancer)
12/2023 - 01/2005
9Neoplasms (Cancer)
12/2023 - 01/2005
3Heart Failure
12/2022 - 02/2007
3Cardiovascular Diseases (Cardiovascular Disease)
02/2021 - 12/2005
3Brain Neoplasms (Brain Tumor)
01/2021 - 02/2009
2Triple Negative Breast Neoplasms
12/2023 - 12/2023
2Fatigue
12/2023 - 01/2017
2Cardiotoxicity
12/2022 - 12/2016
2Disease Progression
05/2021 - 03/2010
2Pathologic Complete Response
01/2019 - 01/2006
2Neutropenia
01/2017 - 06/2013
2Hypercholesterolemia
02/2007 - 12/2005
2Uterine Hemorrhage (Uterine Bleeding)
02/2007 - 12/2005
1Non-Hodgkin Lymphoma (Lymphosarcoma)
12/2022
1Myocardial Ischemia (Ischemic Heart Diseases)
02/2021
1Infections
01/2017
1Febrile Neutropenia
05/2013
1Hypertension (High Blood Pressure)
05/2013
1Neoplasm Metastasis (Metastasis)
02/2009
1Neurologic Manifestations (Neurological Manifestations)
02/2009
1Central Nervous System Diseases (CNS Diseases)
02/2009
1Bone Diseases (Bone Disease)
08/2008
1Spontaneous Fractures (Pathological Fracture)
08/2008
1Ischemia
02/2007
1Arthralgia (Joint Pain)
02/2007
1Hot Flashes
02/2007
1Bone Fractures (Bone Fracture)
02/2007
1Alopecia (Baldness)
01/2006
1Thromboembolism
12/2005
1Endometrial Neoplasms (Endometrial Cancer)
12/2005

Drug/Important Bio-Agent (IBA)

11Trastuzumab (Herceptin)FDA Link
05/2021 - 01/2007
7ErbB Receptors (EGF Receptor)IBA
05/2021 - 11/2009
7Hormones (Hormone)IBA
02/2021 - 12/2005
6Capecitabine (Xeloda)FDA Link
12/2023 - 01/2006
6Letrozole (Femara)FDA LinkGeneric
02/2021 - 12/2005
5Cyclophosphamide (Cytoxan)FDA LinkGeneric
12/2023 - 01/2006
5AnthracyclinesIBA
12/2022 - 05/2009
5TamoxifenFDA LinkGeneric
02/2021 - 12/2005
5human ERBB2 proteinIBA
10/2020 - 11/2009
5Docetaxel (Taxotere)FDA Link
05/2013 - 01/2006
4Fluorouracil (Carac)FDA LinkGeneric
12/2023 - 05/2009
4Epirubicin (Ellence)FDA LinkGeneric
12/2023 - 05/2009
4Aromatase InhibitorsIBA
02/2021 - 12/2005
4taxaneIBA
01/2013 - 01/2006
3SteroidsIBA
11/2011 - 12/2005
2Circulating Tumor DNAIBA
12/2023 - 01/2019
2Methotrexate (Mexate)FDA LinkGeneric
12/2023 - 01/2017
2tucatinibIBA
01/2021 - 10/2020
2Bevacizumab (Avastin)FDA Link
06/2013 - 05/2013
2Doxorubicin (Adriamycin)FDA LinkGeneric
01/2013 - 01/2006
2pertuzumabIBA
03/2010 - 03/2010
14-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA
12/2023
1EnalaprilFDA LinkGeneric
12/2022
1Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
12/2022
1enzalutamideIBA
05/2021
1Androgen Receptors (Androgen Receptor)IBA
05/2021
1Progesterone Receptors (Progesterone Receptor)IBA
01/2021
1abemaciclibIBA
12/2020
1N-acetyltalosaminuronic acid (NAT)IBA
01/2019
1ixabepilone (BMS 247550)FDA Link
06/2013
1Paclitaxel (Taxol)FDA LinkGeneric
06/2013
1Aromatase (CYP19)IBA
06/2012
1ParaffinIBA
06/2012
1Formaldehyde (Formol)FDA Link
06/2012
1DNA (Deoxyribonucleic Acid)IBA
06/2012
1Poly(ADP-ribose) Polymerase InhibitorsIBA
07/2010
1olaparibIBA
07/2010
1Anastrozole (Arimidex)FDA LinkGeneric
11/2009
1Lapatinib (GW572016)FDA Link
02/2009
1Diphosphonates (Bisphosphonates)IBA
08/2008
1Monoclonal AntibodiesIBA
01/2007
1Taxoids (Taxanes)IBA
01/2006
1Fulvestrant (Faslodex)FDA Link
01/2005

Therapy/Procedure

14Therapeutics
12/2023 - 12/2005
8Drug Therapy (Chemotherapy)
12/2022 - 01/2007
4Adjuvant Chemotherapy
12/2023 - 01/2007
2Neoadjuvant Therapy
12/2023 - 01/2019
2Radiotherapy
02/2009 - 08/2008
1Treatment Delay
12/2016
1Intravenous Infusions
06/2013
1Combination Drug Therapy (Combination Chemotherapy)
01/2013